Is Aspen betting on the right HIV prevention product?

Posted in: Healthcare system, HIV, Latest

Aspen Pharmacare has announced that it will not be manufacturing the lenacapavir HIV prevention injection, and that it will instead focus on producing alimatravir, an experimental HIV prevention pill. Catherine Tomlinson explores the reasoning behind Aspen’s decision and assesses what it all means for local pharmaceutical production.

Is Aspen betting on the right HIV prevention product?

AIDS 2026: Some pieces falling into place for monthly HIV prevention pill, but key data not yet in

Posted in: HIV, Latest

If an HIV prevention pill that provides a month of protection at a time performs well in two ongoing clinical trials, it could become the next big thing in HIV prevention after the lenacapavir injection. A new licensing agreement is paving the way for South Africa’s Aspen Pharmacare to produce the pill should the study findings be positive and the drug be registered.